Predicting survival of patients with hypocellular myelodysplastic syndrome

Development of a disease-specific prognostic score system


  • W.-G.T. and A.Q.-C. wrote the paper and analyzed the data. T.K., G.B., E.J., F.R., S.F., W.W., and H.K. contributed patients, helped write the paper, and analyzed the data. S.P. and J.S. performed part of the statistical analysis and helped write the paper. C.B.-R. was the hematopathologist who reviewed cases. G.G.-M. designed the study, analyzed data, contributed patients, and wrote the paper.



Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS.


The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson Cancer Center between 1993 and 2007 and a cohort of 1725 patients with hyper-/normocellular MDS diagnosed during the same time period.


Patients with hypocellular MDS presented more frequently with thrombocytopenia (P < .019), neutropenia (P < .001), low serum β-2 microglobulin (P < .001), increased transfusion dependency (P < .001), and intermediate-2/high-risk disease (57% vs 42%, P = .02) compared with patients with hyper-/normocellular MDS. However, no difference in overall survival was observed between the 2 groups (P = .28). Multivariate analysis identified poor performance status (Eastern Cooperative Oncology Group ≥2), low hemoglobin (<10 g/dL), unfavorable cytogenetics (−7/7q or complex), increased bone marrow blasts (≥5%), and high serum lactate dehydrogenase (>600 IU/L) as adverse independent factors for survival.


A new prognostic model based on these factors was built that segregated patients into 3 distinct risk categories independent of International Prognostic Scoring System (IPSS) score. This model is independent from the IPSS, further refines IPSS-based prognostication, and may be used to develop of risk-adapted therapeutic approaches for patients with hypocellular MDS. Cancer 2012. © 2012 American Cancer Society.


The term myelodysplastic syndrome (MDS) encompasses a heterogenous group of clonal bone marrow disorders characterized by dysplastic changes in hematopoietic progenitors, ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of transformation to acute myeloid leukemia (AML).1, 2 Because of the intrinsic heterogeneity of MDS, several taxonomic and prognostic models have been devised to segregate subsets of patients with MDS, including the French-American-British (FAB),1 World Health Organization (WHO),3 and International Prognostic Scoring System (IPSS) classifications.4 IPSS, currently the most commonly used scoring system, classifies patients based on the percentage of bone marrow blasts, conventional cytogenetics, and number of cytopenias. Although very useful, the IPSS score has its limitations, as it is not applicable to patients with chronic myelomonocytic leukemia (CMML), or those with secondary or treated MDS, and it does not predict the prognosis of MDS in a dynamic manner according to response to therapy. Also importantly, the accuracy of IPSS as a prognostic tool for patients with low-risk MDS has been challenged, as it fails to identify those with lower risk disease and poor prognosis who may benefit from earlier therapeutic intervention. Given these limitations, new prognostic models have been recently proposed, including the WHO classification-based Prognostic Scoring System,5 a low-risk prognostic model,6 and a new global risk model that is applicable to any patient with MDS at any time during the course of therapy.7 A caveat of the global risk model is that hypocellular MDS is largely underrepresented.

Despite the presence of cytopenias in peripheral blood, the bone marrow of patients with MDS is typically hypercellular or normocellular, reflecting excessive bone marrow apoptosis and rapid cellular proliferation.1, 8 However, a subset of patients with MDS present with hypocellular bone marrow (<30% in patients younger than 70 years, or <20% in patients older than 70 years).9-11 The incidence of hypocellular MDS has been reported to be 10% to 20%.10, 11 These cases may be difficult to differentiate from patients with aplastic anemia (AA) based on standard morphological criteria.12, 13 However, hypocellular MDS frequently exhibits abnormal cytogenetics13, 14 and a normal or increased percentage of CD34+ cells in the bone marrow, the latter being markedly decreased in AA.15 AA and hypocellular MDS also share overlapping features that suggest a common pathogenetic link, such as the presence of T-cell–mediated myelosuppression16 and the appearance of a clone of paroxysmal nocturnal hemoglobinuria cells that often predicts a higher probability of response to immunosuppressive therapy.17 Mounting evidence suggests that immunological deregulation underpins the ineffective hematopoiesis that characterizes hypocellular MDS.15, 18 Immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine have been shown to induce sustained hematological responses in approximately 25% of patients with hypocellular MDS.19-22 Factors predicting for response to ATG treatment include age, low/intermediate-1 IPSS score,23 the presence of HLA-DR15,24 and the ratio of CD4 to CD8 cells.25 Further strengthening the link between hypocellular MDS and AA, some patients with AA, even after successful immunosuppressive therapy, may transform to MDS and/or AML at a rate of 2% per year.13, 14, 26

Although hypocellular MDS appears to be a distinct clinicopathological entity with a different prognosis compared with that of its hyper-/normocellular counterpart,11, 23, 27 it is not currently considered a separate entity by the FAB or WHO classifications.1, 3 In addition, several studies have reported that bone marrow hypocellularity predicts for a favorable outcome among patients with MDS, which appears to be independent of IPSS score and cytogenetics.27

To better understand the natural history of hypocellular MDS and improve the prognostic stratification of these patients, we analyzed the associations between disease characteristics and survival in 253 patients with hypocellular MDS and compared this cohort of patients with a cohort of patients with hyper-/normocellular MDS diagnosed at our institution during the same time period. Such analysis rendered several prognostic factors that predict for survival in hypocellular MDS, which were then used to construct a prognostic model.



We retrospectively reviewed clinical, hematologic, and pathological data of all MDS patients diagnosed at The University of Texas MD Anderson Cancer Center (MDACC) between 1993 and 2007. All patients had a confirmed bone marrow diagnosis of MDS and <20% bone marrow blasts according to the WHO classification. All specimens were evaluated by at least 1 hematopathologist at MDACC. In this analysis, hypocellular MDS was defined as <20% bone marrow cellularity, regardless of age. We excluded patients without follow-up visit or unknown treatment history since their initial presentation to MDACC. Patients who received prior MDS treatment (excluding supportive measures) within 6 months before presentation to MDACC were also excluded from the study, because treatment might have contributed to bone marrow hypocellularity in those patients. Patients with MDS secondary to previous chemotherapy or radiation administered for other malignancies were included in the study. This factor was taken into account in the final multivariate analysis. Overall, we identified 253 patients with hypocellular MDS, and 1725 patients with hyper-/normocellular MDS during the 1993-2007 period. Karyotypes were classified according to the International System for Cytogenetic Nomenclature Criteria,28 and IPSS score was calculated as previously published.4 The study was conducted according to the research guidelines of MDACC.

Statistical Analysis

Categorical and continuous variables on all subjects between groups were analyzed by chi-square test and Mann-Whitney U test, respectively. All patients were followed for at least 6 months from their initial presentation to MDACC. Survival was calculated from the day of referral until death from any cause. Observations were censored for patients last known to be alive. Observations of AML progression-free survival were censored at the date of last contact for patients with no report of progression who were last known to be alive. Distributions of survival and progression-free survival were estimated by the method of Kaplan and Meier, and comparisons between subgroups were done using the log-rank test. A Cox proportional hazards regression model was used to assess the ability of patient characteristics to predict survival. Proportional assumptions for each variable and interactions between variables selected in the final model were checked. Patients were randomly divided into 2 subgroups in a 2 to 1 ratio: a study group (n = 169; training set) and a test group (n = 84; validation set).



We retrospectively reviewed clinical and pathological data of 253 patients with hypocellular MDS and 1725 patients with hyper-/normocellular MDS diagnosed at MDACC between 1993 and 2007. A comparison of the clinical characteristics of both MDS cohorts is presented in Table 1. Patients with normo-/hypercellular MDS and those with hypocellular MDS exhibited similar median overall survival (64 vs 71 weeks, P = .312; Fig. 1). However, when only patients with de novo MDS were considered, those with hypocellular MDS appeared to have longer overall survival compared with their normo-/hypercellular counterparts (94 vs 78 weeks, P = .04). Compared with patients with hyper-/normocellular MDS, those with hypocellular MDS presented with lower platelet (P = .019), white blood cell, and neutrophil counts (P < .001), lower serum β-2 microglobulin (P < .001), and increased transfusion dependency (P < .001). Patients with hypocellular MDS also presented with higher-risk disease compared with those with hyper-/normocellular MDS (57% vs 43% intermediate-2/high-risk IPSS score, respectively; P < .001). No significant differences were observed regarding age, sex distribution, hemoglobin level, bone marrow blast percentage, lactate dehydrogenase (LDH) level, performance status, or IPSS cytogenetics between the 2 groups. The rate of AML transformation (11% vs 13 %, P = .481) and median time to AML transformation (26 vs 27 months, P = .327) were also similar. Although there was no difference in overall survival, when we considered de novo cases only, patients with hypocellular MDS had better overall survival than their hyper-/normocellular counterparts (94 vs 78 weeks, P = .040). However, a trend toward shorter overall survival was observed for patients with therapy-related hypocellular MDS (35 vs 46 weeks, P = .069).

Table 1. Patient Characteristics
CharacteristicsHypocellular MDS, n=253Hyper-/Normocellular MDS, n=1725P
  1. Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; BM, bone marrow; CMML, chronic myelomonocytic leukemia; FAB, French-American-British; Int, intermediate; IPSS, International Prognostic Scoring System; LDH, lactate dehydrogenase; RA, refractory anemia; RAEB, RA with excess of blasts; RAEB-T, RAEB in transformation; RARS, RA with ring sideroblasts; WBC, white blood cell count.

Median age, y (range)65 (13-94)67 (16-89).216
Male sex, No. [%]163 [64]1172 [67.9].267
Hemoglobin, g/dL (range)9.6 (5.5-14.5)9.7 (3.7-16.4).786
Platelets, ×109/L (range)61 (2-457)72 (1-1195).019
WBC, ×109/L (range)2.5 (0.2-35.1)4.1 (0.3-99)<.001
ANC, ×109/L (range)0.95 (0-14.20)2.01 (0-74.69)<.001
BM cellularity, % (range)15 (1-20)70 (25-100)<.001
BM blast, % (range)7 (0-19)5 (0-19).098
LDH, IU/L (range)558 (182-3434)571 (72-10,000).155
β-2 microglobulin, mg/L (range)2.4 (0.1-20); n=1873.1 (0.1-20); n=1291<.001
Therapy related, No. [%]62 [25]377 [21.9].219
Transfusion, No. [%]131 [52]486 [28]<.001
Performance status 0-1, No. [%]228 [90]1518 [88].327
IPSS score, No. [%]  <.001
 Low27 [11]297 [18] 
 Int-182 [32]682 [40] 
 Int-2110 [43]515 [31] 
 High34 [13]231 [11] 
FAB classification, No. [%]n=253n= 1725<.001
 RA75 [30]376 [22] 
 RARS20 [8]185 [11] 
 RAEB125 [49]636 [37] 
 RAEB-T28 [11]168 [10] 
 CMML5 [2]360 [21] 
IPSS cytogenetics, No. [%]  .086
 Good135 [53]965 [57] 
 Intermediate32 [13]475 [28] 
 Poor86 [34]263 [15] 
AML transformation by IPSS, No. [%]29 [11]224 [13] 
 Low, n=252 [8]17 [6] 
 Int-1, n=845 [6]72 [11] 
 Int-2, n=11119 [17]87 [17] 
 High, n=134 [31]39 [22] 
Median time to AML, wk (range)26 (1-329)27 (1-460).497
Median survival, wk   
 De novo9478.040
 Therapy related3546.069
Figure 1.

Overall survival of patients with hypocellular or normo-/hypercellular myelodysplastic syndrome is shown.

Prognostic Factors in Hypocellular MDS Patients

To identify disease characteristics that predict for shorter survival, and to develop a prognostic model for patients with hypocellular MDS, we randomly divided the patient cohort in a 2:1 ratio into a study group (n = 169) and a test group (n = 84). Clinical characteristics associated with overall survival in the study group were analyzed using a Cox univariate model, and the results are shown in Table 2. Disease characteristics that are associated with adverse survival included low hemoglobin, low platelet count, low serum albumin, high serum LDH, high serum β-2 microglobulin, bone marrow cellularity, increased bone marrow blast, poor performance status, therapy-related MDS, transfusion dependency, unfavorable cytogenetics, number of cytopenias, and IPSS risk score. We then applied a multivariate Cox regression analysis with stepwise backward selection in this group of patients. All these prognostic factors were included in a multivariate analysis initially. Factors that showed no or only limited statistical significance (P > .01) adjusted for the remaining factors in the analysis were subsequently deleted. We identified 5 parameters that were significantly associated with shorter overall survival based on this analysis. These include hemoglobin <10 g/dL, performance status ≥2, unfavorable cytogenetics (−7/−7q or complex), bone marrow blast ≥5%, and serum LDH >600 IU/L (Table 3). Increased serum β-2 microglobulin level was significantly associated with poor overall survival, which was 27.5 months for β-2 microglobulin <2 mg/L, 19.4 months for β-2 microglobulin between 2 and 3.9 mg/L, and 10.2 months for β-2 microglobulin ≥4 mg/L. However, this factor was not included in the final model, because data were only available in a fraction of patients. To assess the impact of different treatment modalities on survival, we grouped all therapies into 3 categories: 1) supportive care (transfusion and growth factor only), 2) immunosuppressive therapy (ATG/cyclosporine), and 3) others (azacitidine, decitabine, thalidomide, lenalidomide, or low-dose chemotherapy with cytarabine, topotecan, or clofarabine). Importantly, patients who received immunosuppressive therapy had the best overall survival of all 3 groups, further supporting the notion that in at least a subset of cases, the pathogenesis of hypocellular MDS may be driven by deregulation of T-cell immunity. We also evaluated the presence of fibrosis. Twenty-three patients had some evidence of fibrosis, but it was not severe in any case. Fibrosis had no impact on outcome.

Table 2. Prognostic Factors in Hypocellular Myelodysplastic Syndrome (Study Group, n=169)
ParametersCategoryNo.Estimated SurvivalP
Median, mo2 Year, %3 Year, %
  1. Abbreviations: Int, intermediate; IPSS, International Prognostic Scoring System; LDH, lactate dehydrogenase.

Age, y<604222.14740.21750
Hemoglobin, g/dL<1091112512.00001
Platelets, ×109/L<5076113119.02598
Serum albumin, g/dL<48112.12514.00859
Serum LDH, IU/L≤600104224528.00031
Bone marrow cellularity≤10%5215.73324.04725
Bone marrow blast<5%6527.55736.00311
Performance status0-115117.64125.02513
Therapy relatedNo12420.34327.00983
Prior transfusionNo8026.75333.00706
β-2 microglobulin, mg/L<24327.55638.00803
Number of cytopenias0/14826.75621.00049
IPSS risk scoreLow1927.77738.00011
Table 3. Prognostic Factors for Survival Identified by Multivariate Analysis
Prognostic FactorCoefficientP
  1. Abbreviation: LDH, lactate dehydrogenase.

Hemoglobin <10 g/dL0.196.00026
Performance status ≥20.274.00484
Unfavorable cytogenetics0.194.00667
Bone marrow blast ≥5%0.211.00765
Serum LDH >600 IU/L0.196.00990

Construction and Validation of a New Prognostic Model for Hypocellular MDS

Once having identified the factors that independently predict for survival by multivariate analysis, we next developed a prognostic model for patients with hypocellular MDS. Each of the parameters used in the model carried equal weight and was assigned a score of 1. The survival outcomes for patients with each score point are listed in Table 4. To make the model easily applicable in a clinical setting, patients were divided into 3 risk groups based on their total risk scores (Table 4). In the study group, patients with low risk (n = 66; scores 0-1) had a median survival of 30 months, and 2-year and 3-year survival rates of 62% and 44%, respectively. Patients with intermediate risk (n = 44; score 2) had a median survival of 19.4 months, and 2-year and 3-year survival rates of 43% and 20%, respectively. Finally, patients with high-risk disease (n = 59; scores 3-5) in the study group had a median survival of only 7.3 months, and 2-year and 3-year survival rates of 12% and 6%, respectively (Fig. 2, Top). When we applied this new prognostic model to the 84 patients included in the test group, it discriminated 3 discreet groups with distinct survival rates. The median survival for the low-, intermediate-, and high-risk groups in the test group was 55.7, 13.5, and 8.6 months, respectively (Fig. 2, Bottom). The utility of the IPSS risk score in patients with hypocellular MDS has not been validated. To shed some light into the applicability of IPSS in this setting, we next determined the survival of our cohort of patients with hypocellular MDS according to the IPSS risk score in the 3 categories of patients with hypocellular MDS defined by the new prognostic model. Of note, IPSS lacked discriminatory power to further stratify patients with hypocellular MDS in any of the categories (low, intermediate, and high) defined by the new prognostic model regarding overall survival (Fig. 3).

Table 4. Estimated Survival According to Independent Risk Factors in the Study Group (n= 169)
Risk GroupRisk FactorsPatients, No. (%)Median, mo2-Year/ 3-Year Survival, %
Low017 (10)Not reached71/61
149 (29)2759/38
Intermediate244 (26)19.443/20
High339 (23)9.314/7
417 (10)4.712/6
53 (2)20/0
Figure 2.

Overall survival of patients is shown according to the new prognostic model for patients with hypocellular myelodysplastic syndrome in the (Top) study and (Bottom) test groups.

Figure 3.

Overall survival is shown according to the International Prognostic Scoring System (IPSS) in patients with (Top) low-risk, (Middle) intermediate-risk, or (Bottom) high-risk hypocellular myelodysplastic syndrome according to the new prognostic model.

The New Prognostic Model Further Refines IPSS Prognostication in Patients With Hypocellular MDS

Because IPSS scoring is devoid of prognostic value within each of the subcategories defined by the new prognostic model, we next performed the reverse exercise to investigate whether applying our novel risk score system could discriminate distinct subsets of patients within each of the IPSS categories. To that end, we applied the new prognostic model to patients with low/intermediate-1 (Fig. 4, Top) or intermediate-2/high-risk (Fig. 4, Bottom) hypocellular MDS according to IPSS. The new model was able to further stratify patients with low/intermediate-1 IPSS risk into 3 groups (low-, intermediate-, and high-risk MDS) with distinct survival (P < .001). Similarly, the new model stratifies patients with intermediate-2/high IPSS into 3 categories with different overall survival (P < .001), including a low-risk group whose overall survival resembles that of patients in the low/intermediate-1 IPSS categories (Fig. 4, Bottom), supporting the notion that the new model further refines IPSS scoring. In aggregate, these results indicate that the proposed new model has prognostic value that is independent of IPSS.

Figure 4.

Overall survival is shown according to the new prognostic model in patients with (Top) low/intermediate-1 or (Bottom) intermediate-2/high-risk hypocellular myelodysplastic syndrome according to the International Prognostic Scoring System.


The original IPSS classification was designed for patients with newly diagnosed, untreated MDS, but excluded those patients with secondary MDS and CMML with white blood cell counts >12 × 109/L.4 Although still widely used in clinical practice, several new prognostic models have been recently proposed to correct these deficiencies of the original IPSS classification and even to prognosticate patients in a dynamic fashion during the course of therapy.5, 7 The bone marrow of patients with MDS is usually normocellular or hypercellular. However, hypocellularity is present in 10% to 20% of cases of MDS. Although neither the FAB nor the WHO classification system has recognized hypocellular MDS as a distinct entity, several small series have attributed specific clinical and biological characteristics to the hypocellular form of MDS, and have identified this MDS subtype as particularly responsive to immunosuppressive therapies such as ATG and cyclosporine.10, 23, 24, 27 In the absence of typical karyotypic abnormalities, such patients are usually difficult to differentiate from patients with aplastic anemia on the basis of standard morphologic criteria.12, 13, 29 In the current study, we describe the clinical characteristics and outcome of 253 patients with hypocellular MDS, which constitutes the largest case series reported to date. Our study demonstrates important differences between hypocellular MDS and hyper-/normocellular MDS with regard to clinical features and survival that suggest the presence of 2 biologically distinct entities. We have also identified a set of independent prognostic factors that we have integrated into a new risk model with significant prognostic value independent from IPSS.

In our series, the incidence of hypocellular MDS is 12.8% when using a bone marrow cellularity cutoff of 20%, regardless of age. This is consistent with the previously reported incidence of 10% to 20%. Patients with hypocellular MDS more frequently presented with thrombocytopenia, neutropenia, and higher transfusional requirements, even in the absence of significant differences in hemoglobin levels at diagnosis. On the basis of these findings, and given the finding that a higher proportion of patients with hypocellular MDS had poor risk cytogenetics (34% vs 15%), it is not surprising that more patients with hypocellular MDS belonged to the high-risk IPSS categories (intermediate-2/high) compared with those with hyper-/normocellular MDS (56% vs 42%). Notwithstanding these differences, the risk of transformation to AML for patients with hypocellular MDS and for those with hyper-/normocellular MDS were similar, again supporting the notion of a different biology underlying both types of MDS. Another interesting finding is that patients with hypocellular MDS present with lower β-2 microglobulin levels, which is strongly associated with a more favorable survival. A similar association has been well established in patients with chronic lymphocytic leukemia and multiple myeloma. The reason for this association in patients with hypocellular MDS requires further investigation, as it may be directly linked to the pathogenesis of this MDS subtype. Unfortunately, the number of patients in whom β-2 microglobulin levels were available was too low and prevented its entrance into the final model. However, these preliminary results indicating a potential association of β-2 microglobulin with survival, combined with its levels being readily available in most clinical settings, warrants the investigation of the prognostic value of β-2 microglobulin in a large series of patients with hypocellular MDS.

Previous studies investigating the survival of patients with MDS and hypocellularity have produced conflicting results, as some studies have suggested that hypocellularity might be an independent factor for a more favorable outcome, whereas others have failed to confirm this association.27, 30, 31 In the large series of patients presented here we did not observe any significant survival advantage of patients with hypocellular MDS when compared with those with hyper-/normocellular MDS. However, when only patients with de novo MDS were considered, hypocellularity appeared to predict a more favorable survival. This may be partly explained by the higher proportion of patients with secondary hypocellular MDS observed in our case series (25% vs 21.9%) and by the finding that patients with secondary hypocellular MDS had a worse survival than those with secondary hyper-/normocellular MDS (35 weeks vs 46 weeks).

The utility of the original IPSS classification in patients with hypocellular MDS has not yet been confirmed, as the IPSS did not specifically distinguished these patients. In addition, as demonstrated in the present study, in an important fraction of patients (approximately 25%) hypocellular MDS is therapy related and therefore not accounted for by IPSS, and patients with hypocellular MDS were underrepresented in the global risk model, thus highlighting the need for a risk model specific for this MDS subtype. We have developed such a model by using 5 factors identified as independent predictors of survival among patients with hypocellular MDS. This new model stratifies patients with hypocellular MDS into 3 risk categories associated with distinct survival expectations. The new risk model takes into consideration some disease-specific markers such as bone marrow blast burden, cytogenetics, hemoglobin, and serum LDH, as well as patient-specific markers such as performance status. It applies to all patients with hypocellular MDS, including those with secondary MDS and those who received prior therapy. The new risk model is independent of IPSS and is useful for stratification purposes in all IPSS categories. In addition, it allows the identification of patients with intermediate-2/high-risk disease by IPSS whose survival resembles that of patients with lower risk by IPSS, which may have important therapeutic implications. Therefore, the sequential application of the IPSS followed by the new model (but not the reverse sequence) refines the prognostic power of each system used individually in patients with hypocellular MDS.

The development of this new risk model should be interpreted as a first attempt at developing a clinically meaningful tool that warrants further validation in a larger cohort of patients with hypocellular MDS, ideally in the context of an international collaborative effort, to confirm its utility in this specific MDS patient population. The main application of this new risk model is that of predicting long-term outcomes. However, the latter are highly dependent on the efficacy of available therapies. Immunosuppressive approaches have been used in patients with MDS,32-34 and in those responding to such approaches, clonal expansions of cytotoxic CD8+ T cells, which suppress normal hematopoiesis, and CD4+ helper T cells, which promote and maintain autoimmunity, have been demonstrated.35 Factors such as younger age, lower-risk disease, bone marrow hypocellularity, and expression of HLA-DR15 have been invoked as predictors of response to immunosuppressive therapy.23, 24, 27 In the current study, 25 (10%) of patients received immunosuppressive therapy, which appeared to result in improved overall survival compared with that of patients who received either supportive care or other types of MDS-directed therapy. However, it must be emphasized that although hypocellular MDS appears to predict response to immunosuppressive therapy, this finding has not been universally reproduced,36 and other factors may bear similar if not higher weight in determining the probability of response to such therapeutic approaches.37 The identification of such factors is key to target immunosuppressive therapy (eg, cyclosporine, antithymocyte globulin, alemtuzumab) to the subset of patients with MDS most likely to respond to such an approach.

In addition, this analysis has several other limitations that include, for instance, that other newer prognostic models, such as the WHO classification-based Prognostic Scoring System,5 were not evaluated, and that some of the variables, such as β-2 microglobulin, were not available in all patients.

In conclusion, we herein reported on the largest series to date of patients with hypocellular MDS and proposed a new risk model based on a small set of prognostic factors identified by multivariate analysis as predictors of survival independent of IPSS score. This new risk model may be clinically useful in developing risk-adapted treatment modalities for patients with hypocellular MDS.


No specific funding was disclosed.


The authors made no disclosures.